Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

Statements of Cash Flows

 (in CHF thousands)

  For the Years Ended
December 31, 
  Note   2018   2017   2016
Operating activities              
Net loss for the period     (50,951)   (26,411)   (7,096)
Adjustments to reconcile net income for the period to net cash flows:              
Depreciation of property, plant and equipment 4   961   580   278
Finance result, net 12   1,401   3,872   (3,360)
Share-based compensation expense 16   2,518   1,579   1,317
Changes in net employee defined benefit liability 15   437   348   250
Accrued interest 10   50   99  
Changes in working capital:              
Increase in prepaid expenses 6   (924)   (162)   (494)
Increase in accrued income 6   (868)   (1,910)   (842)
Decrease/(increase) in other current receivables 7   698   (401)   (248)
Increase in accrued expenses 9   2,113   2,940   1,564
Decrease/(increase) in deferred income 11   (18)   (156)   476
Increase/(decrease) in long-term debt obligation 10   (53)   204  
Increase/(decrease) in trade and other payables 9   864   (2,853)   2,592
Cash used in operating activities     (43,772)   (22,271)   (5,563)
Interest income 12   29   330   43
Finance costs 12   (335)   (153)   (126)
Net cash flows used in operating activities     (44,078)   (22,094)   (5,646)
               
Investing activities              
Short-term financial assets 5   (30,000)    
Purchases of property, plant and equipment 4   (1,858)   (1,802)   (899)
Rental deposits 5   (178)   (40)  
Net cash flows used in investing activities     (32,036)   (1,842)   (899)
               
Financing activities              
Proceeds from issuance of preferred Series E         13,206
Proceeds from public offerings of common shares,net of underwriting fees 8   111,529     69,388
Transaction costs on public offerings of common shares 8   (2,015)     (4,105)
Proceeds from issuance of common shares 8   5   71   301
Proceeds from long-term debt obligation 10   198   200  
Repayment of short-term debt obligation 10   (339)    
Net cash flows provided by financing activities     109,378   271   78,790
               
Net increase/(decrease) in cash and cash equivalents     33,264   (23,665)   72,245
Cash and cash equivalents at January 1     124,377   152,210   76,522
Exchange gains on cash and cash equivalents     (1,179)   (4,168)   3,443
Cash and cash equivalents at December 31     156,462   124,377   152,210
               
Net increase/(decrease) in cash and cash equivalents     33,264   (23,665)   72,245

 

 

 F-7


© AC Immune 2015